IDEAYA Biosciences(US:IDYA) Prnewswireยท2024-05-23 21:05Core Insights - IDEAYA Biosciences announced preliminary clinical results for darovasertib, a first-in-class oral small molecular inhibitor of protein kinase C (PKC), in a Phase 2 trial for uveal melanoma at the 2024 ASCO Annual Meeting [1][5] Group 1: Clinical Trial Details - The Phase 2 trial involved 15 patients with localized uveal melanoma, treated with darovasertib 300mg twice daily [2] - An initial safety cohort of 3 patients was treated for one month, followed by 12 patients in an expansion cohort for up to six months [2] - As of the database lock, 11 patients completed primary treatment, with 4 remaining on neoadjuvant treatment and 6 receiving adjuvant darovasertib [3] Group 2: Efficacy and Safety Results - Approximately 67% (6 of 9 patients) had confirmed eye preservation, converting to plaque brachytherapy or external beam radiotherapy [3][8] - Median tumor shrinkage was approximately 39% after six months of treatment [3][8] - Darovasertib was generally well tolerated, with drug-related adverse events primarily Grade 1 or Grade 2; 13% reported at least one Grade 3 adverse event, with no serious adverse events observed [4][8] Group 3: Upcoming Presentation - Additional clinical data and follow-up will be presented at the ASCO 2024 oral presentation scheduled for June 3, 2024 [5][9] - The presentation will focus on the safety and efficacy of darovasertib for localized ocular melanoma [9]